.png)
.png)
Professor
Fred Hutchinson Cancer Center
Disclosure(s): Allovir: Advisor/Consultant; Amazon: Grant/Research Support; Ansun Biopharma: Grant/Research Support; EvrysBio: Advisor/Consultant; Gates Ventures: Grant/Research Support; Gilead Sciences: Advisor/Consultant, Grant/Research Support; GlaxoSmithKline: Advisor/Consultant, Grant/Research Support; Helocyte: Advisor/Consultant; Janssen: Advisor/Consultant, Grant/Research Support; Kyorin Pharmaceuticals: Advisor/Consultant; Merck: Advisor/Consultant, Grant/Research Support; Moderna: Advisor/Consultant, Grant/Research Support; Regeneron: Grant/Research Support; ReViral: Advisor/Consultant; Symbio: Advisor/Consultant; Takeda: Grant/Research Support; Vir Biotechnology: Advisor/Consultant, Grant/Research Support
Michael Boeckh, MD, PhD, is the Head of the Infectious Disease Sciences Program, Vaccine and Infectious Disease Division, at Fred Hutchinson Cancer Research Center, and a Professor of Medicine, Division of Allergy and Infectious Diseases, at the University of Washington. He received his MD and PhD degrees from the Freie Universität Berlin, Germany, and trained in internal medicine at the Benjamin Franklin Hospital in Berlin, Germany, and in infectious diseases at the University of Washington. He is an expert in viral infections in the immunocompromised host. Dr. Boeckh is a Fellow of the Infectious Disease Society of America and the current chair of the American Society of Transplantation and Cellular Therapy (ASTCT) Transplant Infectious Disease Special Interest Group. He conducts laboratory research, observational studies as well as clinical trials of all phases, and has authored more than 300 peer-reviewed articles, review articles, practice guidelines and book chapters. He is the co-editor of the Transplant Infectious Disease textbook (4th edition). His CMV research is focused on immune reconstitution after transplantation, viral kinetics, transmission of CMV, and disease management in the immunocompromised patient population. Recently, he also initiated studies to determine the role of CMV reactivation on the outcome of immunocompetent patients with sepsis and respiratory failure. His respiratory virus research focuses on the association of respiratory viruses and airflow obstruction, the adaptive immune response to respiratory viruses, viral dissemination and gene expression signatures as biomarkers for disease severity, as well as management strategies.